These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577 [TBL] [Abstract][Full Text] [Related]
23. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. Hoeper MM; Schwarze M; Ehlerding S; Adler-Schuermeyer A; Spiekerkoetter E; Niedermeyer J; Hamm M; Fabel H N Engl J Med; 2000 Jun; 342(25):1866-70. PubMed ID: 10861321 [TBL] [Abstract][Full Text] [Related]
24. [Long-term treatment of primary pulmonary hypertension with inhaled iloprost]. Hoeper MM; Schwarze M; Ehlerding S; Adler-Schuermeyer A; Spiekerkoetter E; Niedermeyer J; Hamm M; Fabel H Pneumologie; 2001 Jan; 55(1):38-43. PubMed ID: 11236355 [TBL] [Abstract][Full Text] [Related]
25. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Van Albada ME; Loot FG; Fokkema R; Roofthooft MT; Berger RM Pediatr Res; 2008 Mar; 63(3):321-7. PubMed ID: 18287971 [TBL] [Abstract][Full Text] [Related]
26. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Caramaschi P; Volpe A; Tinazzi I; Bambara LM; Carletto A; Biasi D Rheumatol Int; 2006 Dec; 27(2):203-5. PubMed ID: 17006704 [TBL] [Abstract][Full Text] [Related]
27. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study. Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272 [TBL] [Abstract][Full Text] [Related]
28. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis]. Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653 [TBL] [Abstract][Full Text] [Related]
29. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial. Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539 [TBL] [Abstract][Full Text] [Related]
30. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Olschewski H; Hoeper MM; Behr J; Ewert R; Meyer A; Borst MM; Winkler J; Pfeifer M; Wilkens H; Ghofrani HA; Nikkho S; Seeger W Respir Med; 2010 May; 104(5):731-40. PubMed ID: 20153158 [TBL] [Abstract][Full Text] [Related]
31. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension. Stricker H; Domenighetti G; Fiori G; Mombelli G Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827 [TBL] [Abstract][Full Text] [Related]
32. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170 [TBL] [Abstract][Full Text] [Related]
33. [The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension]. Cui N; Yang YH; Xie WM; Ma ZH; Luo L; Wang C Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):522-6. PubMed ID: 19954007 [TBL] [Abstract][Full Text] [Related]